Kelsey Goodwin
Stock Analyst at Guggenheim
(0)
# 4307
Out of 5,312 analysts
17
Total ratings
27.27%
Success rate
-15.48%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
IPSC Century Therapeutics | Reiterates: Buy | n/a | n/a | n/a | 3 | Mar 28, 2025 | |
GNLX Genelux | Initiates Coverage On: Buy | 8 | 2.24 | 257.14% | 1 | Oct 29, 2024 | |
NUVL Nuvalent | Maintains: Strong Buy | 99 105 | 63.02 | 66.61% | 2 | Sep 16, 2024 | |
URGN UroGen Pharma | Initiates Coverage On: Buy | 40 | 9.66 | 314.08% | 1 | Aug 22, 2024 | |
MGNX Macrogenics | Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | n/a | n/a | n/a | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Oct 31, 2022 |